Compound high-quality criteria: a new vision to guide the development of drugs, current situation

Drug Discovery Today
Serge MignaniJean-Pierre Majoral

Abstract

For several decades, the pharmaceutical industry has suffered due to major issues such as reductions of the number of FDA approved drugs and biologics. Several analyses have been highlighted that the 'druglikeness' is one of the strategies to improve succeed rates of screening such as, for instance, high-throughput screening (HTS), and then hits (as starting point), leads and clinical candidates. It is clear that the improvement of compound quality accelerates the drug discovery projects. The monitoring of several indices to avoid 'molecular obesity' (ADMET problems) of final drugs from good-quality 'low-fat' starting points represents today a powerful strategy of optimization process. The development of the new guides to find drugs highlighting attempts at improving the attrition rate from hits to final medicines by focusing on how to improve the druggability of hits, leads and drugs during the drug discovery process represents a key approach to design next better generation of medicines.

References

Jan 1, 1996·Medicinal Research Reviews·R S BohacekW C Guida
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·I D KuntzP A Kollman
Apr 20, 2001·Journal of Medicinal Chemistry·H van De WaterbeemdD K Walker
May 31, 2002·Journal of Medicinal Chemistry·Daniel F VeberKenneth D Kopple
Jul 9, 2002·Journal of Combinatorial Chemistry·Tudor I OpreaAnna-Lena Ungell
Feb 7, 2003·Combinatorial Chemistry & High Throughput Screening·Alexander AlanineAndrew W Thomas
Apr 28, 2004·Drug Discovery Today·Andrew L HopkinsAlexander Alex
Jun 9, 2004·Current Opinion in Chemical Biology·Mike M Hann, Tudor I Oprea
Aug 3, 2004·Nature Reviews. Drug Discovery·David C ReesRobin Carr
Dec 17, 2004·Nature·Christopher Lipinski, Andrew Hopkins
Apr 2, 2005·Journal of Medicinal Chemistry·Philip J HajdukStephen W Fesik
Apr 6, 2005·Drug Discovery Today·Cele Abad-Zapatero, James T Metz
Jul 19, 2005·Drug Discovery Today·Robin A E CarrDavid C Rees
Feb 7, 2006·Current Medicinal Chemistry·Luca Costantino, Daniela Barlocco
Feb 24, 2006·Chemical Biology & Drug Design·Adam J RubenErnesto Freire
Mar 15, 2006·Drug Discovery Today·David G LloydTudor I Oprea
Apr 4, 2006·Drug Discovery Today·Ricardo Macarron
Jul 4, 2006·Current Opinion in Chemical Biology·Thomas H KellerZheng Yin
Jul 15, 2006·Nature Biotechnology·Gaia V PaoliniAndrew L Hopkins
Aug 5, 2006·Nature Reviews. Drug Discovery·Robert A CopelandThomas D Meek
Jan 5, 2007·Annual Review of Biophysics and Biomolecular Structure·Michael K Gilson, Huan-Xiang Zhou
Feb 10, 2007·Nature Reviews. Drug Discovery·Philip J Hajduk, Jonathan Greer
Jun 15, 2007·Journal of Medicinal Chemistry·Gergely M Makara
Jun 29, 2007·Journal of Computer-aided Molecular Design·Juri PärnMatthias Rarey
Nov 1, 2007·Nature Reviews. Drug Discovery·Paul D Leeson, Brian Springthorpe
Mar 5, 2008·Current Opinion in Chemical Biology·Thomas Hesterkamp, Mark Whittaker
Apr 3, 2008·Journal of Medicinal Chemistry·Charles H ReynoldsScott D Bembenek
Apr 15, 2008·Drug Discovery Today·Giulio VistoliBernard Testa
Jul 25, 2008·ChemMedChem·Marcel L Verdonk, David C Rees
Nov 26, 2008·Drug Discovery Today·Masaya OritaTatsuya Niimi
Dec 17, 2008·Journal of Medicinal Chemistry·Magid Abou-Gharbia
Feb 28, 2009·Nature Reviews. Drug Discovery·György M Keserü, Gergely M Makara
May 12, 2009·Drug Discovery Today·Gianni Chessari, Andrew J Woodhead
May 16, 2009·Drug Discovery Today·Gerdien E de KloeIwan J P de Esch
Sep 2, 2009·Bioorganic & Medicinal Chemistry Letters·Ted W JohnsonMartin Edwards
Sep 29, 2009·European Journal of Medicinal Chemistry·Amin MirzaJóhannes Reynisson
Nov 3, 2009·Bioorganic & Medicinal Chemistry Letters·Christian TyrchanSorel Muresan
Dec 2, 2009·Nature Reviews. Drug Discovery·Bernard Munos
Dec 5, 2009·Nature Reviews. Drug Discovery·John E LadburyErnesto Freire
Jun 16, 2010·Drug Discovery Today·Rachel L ClarkAlan L Harvey
Jul 29, 2010·Current Opinion in Chemical Biology·Hao Lu, Peter J Tonge
Aug 6, 2010·Drug Discovery Today·Stéphanie PérotBruno O Villoutreix
Aug 31, 2010·Drug Discovery Today·György G Ferenczy, György M Keserũ
Oct 23, 2010·Pharmaceutical Research·Young Bin Choy, Mark R Prausnitz

❮ Previous
Next ❯

Citations

Aug 30, 2016·ACS Chemical Biology·Lewis H MervinAndreas Bender
Oct 1, 2016·Journal of Chemical Information and Modeling·Govindan SubramanianRajiah Aldrin Denny
Nov 5, 2019·Journal of Internal Medicine·J E ChobyD S Weiss
Aug 21, 2019·Chemistry : a European Journal·Oleksandr O GrygorenkoDuncan B Judd
Sep 1, 2019·Alzheimer's Research & Therapy·Jeffrey CummingsPhilip Scheltens
Jul 28, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Serge MignaniGiovanni Lentini
Jul 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Serge MignaniJean-Pierre Majoral

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Current Opinion in Drug Discovery & Development
Thierry Langer, Eva Maria Krovat
Journal of Medicinal Chemistry
Akos TarcsayGyörgy M Keserü
Drug Discovery Today
Alain J van GoolErik D Sprengers
Nature Reviews. Drug Discovery
Ismail Kola, John Landis
© 2022 Meta ULC. All rights reserved